Trading Halt
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Amplia Therapeutics Limited has requested a trading halt for its securities pending the release of an announcement regarding clinical trial results. The halt is necessary for the company to assess new data and prepare an appropriate announcement in an orderly manner. The trading halt will remain in effect until the earlier of the announcement or the commencement of normal trading on a specified date.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-550
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Pause in Trading
- Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
- Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
- Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
- Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
Later from Amplia Therapeutics
- Amplia Reports Improved Responses & Survival in ACCENT trial
- Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
- Amplia Therapeutics Halts Recruitment in AMPLICITY Trial
- Accent Trial Mature Data Presented at International Conference
- Amplia and ANZGOG announce Ovarian Cancer Study
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics